Baird Maintains Neutral on Elevance Health, Raises Price Target to $393

Benzinga Newsdesk www.benzinga.com Positive 71.9%

Neg 0% Neu 0% Pos 71.9%

Baird analyst Michael Ha maintains Elevance Health (NYSE:ELV) with a Neutral and raises the price target from $331 to $393.